<DOC>
	<DOCNO>NCT00823316</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy PROMOSTEM ( human umbilical cord blood-derived mesenchymal stem cell ) dose 1 5x1,000,000 hMSC/kg subject promotion engraftment prevention graft rejection Graft-Versus-Host Disease unrelated hematopoietic stem cell transplantation child acute leukemia .</brief_summary>
	<brief_title>Safety Efficacy Study Umbilical Cord Blood-Drived Mesenchymal Stem Cells Promote Engraftment Unrelated Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>- Hematopoietic stem cell transplantation ( HSCT ) procedure progenitor cell capable reconstitute normal bone marrow function administer patient . This procedure use treat adult child life-threatening hematological malignancy congenital immunodeficiency disorder . - In HSCT , therapeutic goal elimination disease enrichment regenerate capacity achieve engraftments result continued generation functional blood element engraft live cell . Transplantation unrelated hematopoietic stem cell originate either adult bone marrow peripheral blood often lead graft-versus host-disease ( GvHD ) , opportunistic infection graft failure transplantation . - In HSCT , MSC use therapy GvHD complication . The aim MSC infusion HSCT use cell ' immunomodulatory effect promote engraftment reduce immunological reaction give rise GvHD . - There grow interest co-transplantation MSC HSC improve donor outcome unrelated HSCT condition .</detailed_description>
	<criteria>1 . Patient age 2~19 year old plan unrelated hematopoietic stem cell transplantation acute leukemia 2 . Patient never experience hematopoietic stem cell transplantation 3 . Patient must acute leukemia complete remission . 4 . Patients must ECOG 0~2 . 5 . No moderate sever organ dysfunction : Ejection fraction &gt; 45 % ; Creatinine &lt; 2.0 mg/ml ; Serum bilirubin &lt; 2 mg/ml ; AST/ALT &lt; 200 IU/L . 6 . Patient must transplantation different source hematopoietic stem cell bone marrow cord blood . 7 . Patient must infection need administration nonoral antibiotic . 8 . No active severe infection derive form virus fungus . 9 . Each patient / patient 's guardian must sign write informed consent . 1 . Patient previously receive hematopoietic stem cell transplantation . 2 . Patient plan relate hematopoietic stem cell transplantation . 3 . Patient severe internal disease . 4 . Patient enrol another clinical trial study within last 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Mesenchymal Stem Cells</keyword>
	<keyword>Allogeneic Transplantation</keyword>
	<keyword>Engraftment</keyword>
	<keyword>GvHD</keyword>
	<keyword>Childhood</keyword>
	<keyword>unrelated HSCT</keyword>
</DOC>